[Influence of sex on immediate and late results of percutaneous coronary angioplasty].

Prior studies have reported worse results after percutaneous transluminal coronary angioplasty (PTCA) in women than in men. However, recent data suggest that this difference is less marked. The aim of our study is to evaluate whether the procedural outcome is equal in the two genders.

[Asymptomatic cor triatriatum sinister in adulthood].

Cor triatrium sinister is a rare congenital disease (0,1% of cases of congenital heart disease). Cor triatrium is recognized by the finding of an abnormal fibromuscular membrane that subdivise the left atrium into posterosuperior and anteroinferor chambers. This anomaly creates an obstacle to the venous pulmonary flow.

[Short coupled variant of torsade de pointes: our experience and review of the literature].

We present three cases of short-coupled variant of torsade de pointes with review of the literature. These women presented with syncope or presyncope due to torsade de pointes initiated by a short-coupled premature ventricular beat and without evidence of prolonged QT. There were no electrolyte disturbances in all cases, no apparent structural heart disease in two cases and a mild interventricular septum hypertrophy in the other case.

[Role of fibrin D-dimer in acute coronary syndrome. Prospective study of 22 cases].

Fibrin D-dimer are the consequence of an excess of fibrinolysis. The raise of their level in coronary heart disease seems to be helpful to enhance the diagnosis of coronary ischemia. Prospective study over 4 months, including 22 patients (16 male, 6 female) divided in 2 subgroups: Group I: 10 patients investigated for stable angina Group II: 12 patients investigated for ACS without ST elevation.

[GPIIB/IIIA blockade after high-risk angioplasty: new perspectives].

The treatment of acute coronary syndromes knows today revolution, with the clinical use of platelet glycoprotein IIb/IIIa inhibitors. The benefit of these agents as adjunctive treatment for percutaneous coronary intervention has been substantial and consistently proved among trials; however patients undergoing revascularization after drug discontinuation demonstrated a moderate event reduction. In this analysis, including the entire large-scale trial experience of intravenous glycoprotein IIb/IIIa inhibitors, we try to evaluate this therapeutic class in the high risk coronary intervention, in patients with acute coronary syndromes primarily medically managed, and in combination therapy with thrombolytics in the acute myocardial infarction.

[Role of low-molecular-weight heparin in acute coronary syndromes].

Looking to their efficiency in the treatment of venous thrombosis and the problems caused by non fractioned heparins (NFH) in the treatment of acute coronary syndromes, several studies were realised to prove the interests of fractioned heparins (FH) as good alternative therapeutics in acute coronary syndromes. A fist attempt, FRISC study, showed that dalteparin was superior to the placebo given in patients receiving aspirin (75 mg daily). In the FRIC study the pursuit of dalteparin between the sixth and the fortieth day, at a low dose, don't give benefits compared to aspirin given simply.